Abstract 1 INTRODUCTION ORIGINAL ARTICLE
|
|
- Gabriella Joseph
- 5 years ago
- Views:
Transcription
1 Received: 5 October 2017 Revised: 2 November 2017 Accepted: 6 November 2017 DOI: /jce ORIGINAL ARTICLE Feasibility of percutaneous left atrial appendage closure using a novel LAmbre occluder in patients with atrial fibrillation: Initial results from a prospective cohort registry study Shaojie Chen MD, PhD Boris Schmidt MD, FHRS Stefano Bordignon MD Fabrizio Bologna MD Takahiko Nagase MD Nikolaos Tsianakas MD Laura Perrotta MD K. R. Julian Chun MD Cardioangiologisches Centrum Bethanien Frankfurt Am Main, Medizinische Klinik III, Markuskrankenhaus, Frankfurt Am Main, Germany Correspondence Shaojie Chen, MD, PhD and K. R. Julian Chun, MD, Cardioangiologisches Centrum Bethanien, Medizinische Klinik III, Markuskrankenhaus, Wilhelm-Epstein Straße 4, Frankfurt am Main, Germany. drsjchen@126.com; J.chun@ccb.de Disclosures: None. Abstract Background: The LAmbre TM occluder is a novel device for percutaneous left atrial appendage closure (LAAC). The presented study aimed to report the initial experience in implantation of the novel LAmbre for LAAC in patients with nonvalvular AF. Methods: We conducted a prospective, observational, cohort registry study to evaluate the feasibility of percutaneous LAAC using the LAmbre system. Results: Thirty patients (15 female, mean age 77.6 ± 8.9 years) who had high risks of stroke and contraindications for oral anticoagulation were prospectively enrolled in this registry study. The mean CHA2DS2-VaSc was 3.9 ± 1.5, and the mean HAS-BLED score was 4.1 ± 1.0. Twenty (66.7%) patients had chicken-wing LAA morphology. The implant success rate was 100%. The mean fluoroscopic time and procedure time were 3.5 ± 1.9 and 29.0 ± 10.1 minutes, respectively. No significant procedure-related complications were observed during in-hospital and acute clinical follow-up. Conclusion: In this preliminary study, the LAmbre occluder showed an excellent implant success rate, favorable implant property, and very low incidence of complications. Larger sample, randomized studies are further warranted. KEYWORDS atrial fibrillation, cardiac catheter, LAA occluder, LAmbre, left atrial appendage, left atrial appendage occlusion, stroke 1 INTRODUCTION Atrial fibrillation (AF) is the most common cardiac arrhythmia. Around 20 30% of strokes are attributable to AF, and more may be associated with undiagnosed subclinical AF. 1 Oral anticoagulation therapy using vitamin K antagonists or novel oral anticoagulants has been shown to significantly reduce the rate of stroke in patients with AF. 1 Despite the efficacy of the pharmacotherapy, complex drug interactions, poor patients compliance, risk of major bleeding particularly in patients with impaired liver, or renal functions limit their clinical administration in selected patient groups. 2 Thus, a nonpharmacological approach to prevention of stroke in patients with AF seems rational. Previous research showed that up to 90% of left atrial thrombi were located in the left atrial appendage (LAA) among patients with nonvalvular AF. 3 Prior large randomized trials have shown promising results that percutaneous transcatheter occlusion of the atrial appendage by LAA occluder device was noninferior to conventional warfarin therapy in patients with nonvalvular AF in terms of efficacy. 4,5 However, a higher rate of adverse safety events in the LAA device group should be noted. Although the implant success rate is becoming increasingly higher and complication events are decreased in recent years, there are still anatomically and technically complicated cases where novel devices J Cardiovasc Electrophysiol. 2017;1 7. wileyonlinelibrary.com/journal/jce c 2017 Wiley Periodicals, Inc. 1
2 2 CHEN ET AL. FIGURE 1 LAmbre device design and angiography guided implantation [Color figure can be viewed at wileyonlinelibrary.com] with a better design could facilitate the procedure and thus may potentially improve the clinical outcome. The LAmbre LAA occluder (Lifetech Scientific [Shenzhen] Co., Ltd., Shenzhen, China) has been recently recognized with the Conformité Européenne (CE) mark. Its novel designs included: (1) slim delivery system, (2) double stabilization system design, and (3) flexible waist and size adaptive cover. In this study, we report the initial periprocedural data of a prospective cohort patients indicated to LAA closure (LAAC) using the novel LAmbre LAA occluder device. 2 METHOD 2.1 Patients Between October 2016 and August 2017, consecutive patients with nonvalvular AF (without significant mitral stenosis or artificial heart valves or valve repair) who were scheduled for percutaneous LAAC with the LAmbre device were prospectively included in the study at the Cardioangiologische Centrum Bethanien (CCB), Frankfurt, Germany. All patients were enrolled in the institutional registry database (Number: LAAO-LAmbre-CCB). The inclusion criteria were: 18 years and older, both sexes, paroxysmal, persistent or permanent nonvalvular AF, high risk for stroke (CHADS2 score 2), contraindication to long-term oral anticoagulation therapy, e.g., patients with bleeding events after anticoagulation therapy, or intolerance or refusal to take warfarin; we also included patients who demonstrated isolated noncontractile LAA after multiple AF ablation procedures. The exclusion criteria were: (1) patients who had rheumatic, significant degenerative, or congenital valvular heart diseases, artificial heart valve replacement operation; (2) acute myocardial infarction or unstable angina, decompensated heart failure (New York Heart Association functional class III IV), or heart transplantation; (3) stroke or
3 CHEN ET AL. 3 FIGURE 2 LAmbre TEE guided device implantation [Color figure can be viewed at wileyonlinelibrary.com] transient ischemic attack (TIA) within 30 days; (4) patients with atrial septal occluder; (5) clinical conditions not allowing transesophageal echocardiography (TEE) and sedation; (5) poor peripheral vessel access not allowing device delivery; (6) echocardiography exclusion criteria: left ventricular ejection fraction (LVEF) 30%; presence of LAA thrombus; significant mitral valve stenosis (the area of mitral valve 2cm 2 ); significant and unexplained pericardial effusion ( 4cm 2 ). All clinical, periprocedural, echocardiographic, and outcome variables were prospectively collected. The study conduction complied with the Declaration of Helsinki and was approved by the institution. Informed consent was obtained from the included patients before the procedure. 2.2 The LAmbre device The LAmbre (Lifetech Scientific [Shenzhen] Co., Ltd.) is a CE recognized LAA closure device. As shown in Figure 1, it is self-expanded and consists of: (1) 8- to 10-Fr delivery sheath (delivery system), (2) hook-embedded umbrella, and (3) size selective cover. The umbrella has eight small distal hooks engaging into LAA walls and eight U- shaped ends trapping in LAA trabeculations (double stabilization system design). The umbrella and the cover are connected with a short central waist that acts as an articulating, compliant connection between both, allowing the cover to self-orient to the atrium wall. The LAmbre LAA occluder is constructed from a nitinol mesh and polyester membranes. The proximal cover is filled with sewn-in polyethylene terephthalate fabric. There are different cover sizes which could be selected for the same umbrella size. 6 General size information of the LAmbre device including Umbrella-Cover-Delivery system is presented in Supplementary File 1 (referred to: lifetechmed). 2.3 Device implantation The method for the device implantation was published previously. 7,8 In brief, all procedures were performed by experienced operators. Patients were under deep sedation by using boluses of midazolam and a continuous infusion of propofol (1%). A TEE was used to rule out intracardiac and LAA thrombus. After a single transseptal puncture, the transseptal sheath was exchanged with LAmbre delivery sheath and it was continuously flushed with heparinized saline (20 ml/h). (After selective LAA angiogram, the LAA was directly cannulated using a semireleased umbrella creating a ball-shaped figure or the 10F delivery sheath was exchanged over the wire in the LAA orifice.) Activated clotting time was adjusted to > 250 seconds during the procedure. The size of the device was chosen based on angiographic and TEE measurements. The degree of device oversizing was based on the anatomy of the LAA, manufacturer's recommendation, and the experience of the operator. Successful device position was defined as no or minimal contrast leak ( 3 mm) into LAA by angiography as well as TEE. Figures 1 and 2 showed the angiography- and TEE-guided implantation process of the device. Major complications were defined as periprocedural death, cardiac temponade, stroke, embolism, pericardial effusion, and major bleeding. Minor complications were defined as minor bleeding or vascular complications without the need for further intervention or transfusion or prolonged hospitalization.
4 4 CHEN ET AL. TABLE 1 Baseline characteristics of the included patients TABLE 2 Periprocedural data Patients' characteristics Sample size, n 30 Female, n (%) 15 (50.0%) Age (y) 77.6 ± 8.9 Height (cm) ± 9.9 Weight (kg) 76.9 ± 14.9 BMI (kg/m 2 ) 26.5 ± 3.9 Paroxysmal AF, n (%) 14 (46.7%) Nonparoxysmal AF, n (%) 16 (53.3%) Heart failure, n (%) 4 (13.3%) Hypertension, n (%) 22 (73.3%) Age > 75, n (%) 20 (66.7%) Diabetes, n (%) 9 (30%) Previous stroke/tia, n (%) 4 (13.3%) Vascular diseases, n (%) 5 (16.7%) Coronary artery disease, n (%) 15 (50%) Liver/renal dysfunction, n (%) 15 (50) Labile INR, n (%) 2 (6.7%) Drugs predisposing to bleed 30 (100%) Bleeding events, n (%) 21 (70%) *GI bleeding, n (%) 12 (57.1%) *Non-GI bleeding, n (%) 9 (42.9%) CHADS-VASc score 3.9 ± 1.5 HAS-BLED score 4.1 ± 1.0 Anticoagulation pre-procedure 30 (100%) Apixaban, n (%) 11 (36.7%) Rivaroxaban, n (%) 6 (20%) Warfarin, n (%) 13 (43.3%) BMI = body mass index; GI = gastrointestinal. *Drugs predisposing to bleed: anticoagulant. For the first 6 months after procedure, patients are scheduled to be treated with dual antiplatelet inhibition using 300 mg aspirin (ASA) and 75 mg clopidogrel once daily, followed by the ASA therapy. Follow-up was performed by conventional clinical visits. Six weeks to 6 months after the procedure patients underwent follow-up TEE to evaluate the LAA stability and sealing and to rule out the presence of pericardial effusion or embolization. 2.4 Statistical analysis The results are described as mean ± standard deviation (SD) for normally distributed data or median and interquartile ranges were used when appropriate. Statistical analyses were performed using the SPSS software version 17.0 (Chicago, IL, USA). 3 RESULTS As shown in Table 1, during the study period, 30 patients (15 female, mean age 77.6 ± 8.9 years) underwent percutaneous LAA occlusion Patients undergoing implantation, n 30 Presenting sinus rhythm during procedure, n (%) 22 (73.3%) LAA size (mm) 21.2 ± 4.4 Device size (mm) 25.9 ± 5.4 Oversize (mm) 4.7 ± 1.8 Chicken-wing LAA, n (%) 20 (66.7%) Reposition, mean ± SD 0.7 ± 1.1 Reposition = 0, n (%) 16 (53.3%) Reposition > 2, n (%) 1 (3.3%) Success, n (%) 30 (100%) Fluoroscopy time (min) 3.5 ± 1.9 Procedure time (min) 29.0 ± 10.1 Complications Periprocedural death, n (%) 0 Stroke, n (%) 0 Thrombosis, n (%) 0 Air embolism, n (%) 0 Cardiac temponade, n (%) 0 Pericardial effusion, n (%) 0 Major bleeding of access site, n (%) 0 Postprocedure dual antiplatelet, n (%) 25 (83.3%) Dual antiplatelet at discharge, n (%) 29 (96.7%) Remain on anticoagulation, n (%) 1 (3.3%) Follow-up TEE after 6 weeks to 6 months, n (%) 25 (83.3%) Device dislodgment, n (%) 0 Thrombosis in LA, n (%) 0 Residual flow > 5 mm, n (%) 0 Pericardial effusion, n (%) 0 using the LAmbre occluder. All patients had nonvalvular AF (14 paroxysmal and 16 nonparoxysmal AF). The mean CHA2DS2-VaSc score was 3.9± 1.5. Fifteen (50%) patients had coronary heart disease, 15 (50%) patients had impaired liver or renal function, and 21 (70%) patients had clinical bleeding events, including 12 (57.1%) patients who had gastrointestinal (GI) bleeding. The mean HAS-BLED score was 4.1 ± 1.0. During procedure, no patient required general anesthesia. As shown in Table 2, the LAmbre device was successfully implanted in all 30 (100%) patients. Twenty patients (66.7%) had chicken-wing LAA morphology including 1 patient who had twice failed procedures previously using Watchman and Amulet devices implantation because of very challenging LAA morphology. Figure 3 shows the implantation of LAmbre device in a challenging LAA anatomy case. Overall, as shown in Table 2, the mean LAA size was 21.2 ± 4.4 mm, the mean device size was 25.9 ± 5.4 mm. The mean oversize was 4.7 ± 1.8 mm, the median LAA device oversizing of LAA was 5 mm (range 3 6 mm). The mean fluoroscopic time and procedure time were 3.5 ± 1.9 and 29.0 ± 10.1 minutes. Sixteen patients (53.3%) underwent direct device implantation without additional device reposition. No significant procedure-related complications were observed during inhospital observation.
5 CHEN ET AL. 5 FIGURE 3 LAmbre in a challenging anatomy Mean TEE follow-up was 52 ± 16 day after the procedure. Twentyfive of the 30 patients (83.3%) underwent TEE follow-up after procedure. Of them, 16 (64%) patients had no leak jet, 5 (20%) patients had leak jet 2 mm, 3 (12%) patients had leak jet 3 mm, and 1 (4%) patient had leak jet 4 mm. All patients fulfilled adequate sealing and good stability of the device by TEE follow-up. Twenty-five (83.3%) out of 30 patients completed 6 weeks to 6 months TEE follow-up; no complications (device dislodgement, LA thrombosis, pericardia effusion) were found. The antiplatelet and anticoagulation therapy after LAAO procedure is summarized in Table 2. Postprocedure dual-antiplatelet therapy was administered right after the implant in 25 (83.3%) patients, and another 4 patients received their dual-antiplatelet therapy at discharge (1 2 days later) considering the bleeding risk right after the procedure and TEE; another one patient had LAA isolation before LAAO and thus remained on anticoagulation therapy. 4 DISCUSSION These initial results show the feasibility and safety property of the LAmbre occluder for catheter-based LAA occlusion among patients with AF who had high risk of stroke and contraindications for oral anticoagulants. In review of the existing data, several devices have been proposed to achieve durable LAA closure using a percutaneous catheter approach, and the Watchman device (Boston Scientific) is the most investigated LAA occluder. The Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation (PROTECT-AF) trial was the first large randomized trial to test the Watchman device. 4 Seven hundred and seven patients with nonvalvular AF were enrolled and randomized to long-term warfarin or device therapy. During a mean follow-up of 18 months, the primary efficacy (composite endpoint of stroke,
6 6 CHEN ET AL. systemic embolism, and cardiovascular death) event rate was not significantly different in both groups. The PROTECT-AF study demonstrated the noninferiority of the Watchman device as compared with standard therapy with warfarin. Furthermore, the long-term follow-up data of the PROTECT-AF trial published in 2014 demonstrated that during a mean follow-up of 3.8 years the device group was associated with less combined endpoint of stroke, systemic embolism, and cardiovascular and all-cause death compared with warfarin. These favorable outcomes of the device were driven largely by lower rates of hemorrhagic stroke as well as hemorrhagic stroke-related deaths. 5 Despite the promising results of the LAAC device therapy, its complication rate should be noted. In the PROTECT-AF study, the device implantation success rate was 91%, and the device group was accompanied with a higher risk of procedure complications such as pericardial effusion and procedural stroke. Primary safety adverse events occurred more frequently in the device group than in the control group (7.4 vs. 4.4 per 100 patient-years; RR 1.69). The complications associated with LAAC device implantation were typically observed early in the periprocedural period. 4 In the Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with Atrial Fibrillation Versus Long Term Warfarin Therapy (PREVAIL) study, the device implantation success rate was increased to 95%, and safety events (composited of acute occurrence of death, ischemic stroke, systemic embolism, and procedure-related complications requiring intervention) were decreased to 2.2% of the patients. 9 However, there are still anatomically and technically complicated cases where novel devices with a better design could facilitate the procedure and thus may improve the clinical outcomes. Although the presented study is an initial clinical experience, the preliminary data show excellent results in terms of implantation success and safety properties. By the definition (minimal leak 3 mm), the implantation success was achieved in all enrolled patients including 66.7% patients with complicated chicken-wing LAA anatomy. More than half of the patients were successfully implanted the device without reposition. The average fluoroscopic time was 3.5 minutes and most procedures were completed within 30 minutes. There were no periprocedural complications with respect to adverse events such as death, stroke, embolism, myocardial infarction, cardiac temponade, pericardial effusion, and access site complications. There were no complications found with echocardiography on discharge and acute clinical observation. Twenty-five out of 30 patients completed TEE follow-up; no complications (device dislodgement, thrombosis, pericardial effusion) were observed. These results could be explained by the increasing experience of the operators in LAA closure. Furthermore, we have to acknowledge the favorable design of the LAmbre device. This new device is highly adaptable to different LAA morphologies, and it can be quite useful in difficult anatomies (as shown in Figure 3). The combination of distal hooks and the U-shaped ends (double stabilization system), the option of different cover sizes for the same umbrella size, and the central flexible waist design could help to achieve complete sealing and good device stabilization particularly in complex cases. The LAmbre designed with a smaller (8- to 10-Fr) delivery sheath (compared with Fr for Watchman) is also a distinguishing feature of the device, and this may contribute to a reduced risk of vessel access complications. The major limitation of this study is the single-center, observational nature and the sample size of the study was small. However, as a feasibility and safety assessment study for a novel LAAC device, this is by far to our knowledge the largest cohort reporting the periprocedural and short-term clinical results of the LAmbre device. The data showed excellent results of the device implantation, and the fact that all the procedures were performed by experienced operators in a high volume heart center should be taken into account. The presented study only focused on the periprocedure and acute outcomes after the device implantation, although, based on our previous study, the risk of occurrence procedure-related safety events in long-term follow-up was quite low. 6,7 Nonetheless, larger sample size, multicenter, comparative, randomized studies with long-term follow-up are warranted. 5 CONCLUSION This prospective, observational, cohort study presents excellent periprocedural and short-term clinical outcome data on catheterbased LAAC using the novel LAmbre LAA occluder for stroke prevention in patients with nonvalvular AF who had contraindications of oral anticoagulation therapy. Further randomized studies with long-term follow-up are warranted. ACKNOWLEDGMENT We thank all the participants in this study. We thank all the CCB (Cardioangiologisches Centrum Bethanien Frankfurt) Team members for their clinical and scientific contribution. We appreciate the technical support from Lifetech Scientific. Dr. Shaojie Chen receives the Fellowship Awards from European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC). ORCID Shaojie Chen MD, PhD REFERENCES 1. Kirchhof P, Benussi S, Kotecha D, et al ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37: Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15: Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61: Holmes DR, Reddy VY, Turi ZG, et al. PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy
7 CHEN ET AL. 7 for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial. Lancet. 2009;374: Reddy VY, Sievert H, Halperin J, et al. PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: A randomized clinical trial. JAMA. 2014;312: Lam YY, Yan BP, Doshi SK, et al. Preclinical evaluation of a new left atrial appendage occluder (Lifetech LAmbre TM device) in a canine model. Int J Cardiol. 2013;168: Chun KR, Bordignon S, Urban V, et al. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: A prospective single-center experience. Heart Rhythm. 2013;10: Schmidt B, Bordignon S, Fuernkranz A, Perrotta L, Scherer D, Chun KR. Decennial analysis of interventional left atrial appendage closure. J Cardiovasc Electrophysiol. 2015;26: Holmes DR, Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial. J Am Coll Cardiol. 2014;64:1 12. SUPPORTING INFORMATION Additional Supporting Information may be found online in the supporting information tab for this article. How to cite this article: Chen S, Schmidt B, Bordignon S, et al. Feasibility of percutaneous left atrial appendage closure using a novel LAmbre occluder in patients with atrial fibrillation: Initial results from a prospective cohort registry study. J Cardiovasc Electrophysiol. 2017;00:1 7.
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationPatients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationAtrial fibrillation (AF) affects approximately 33 million
Emerging Options for Anticoagulation in LAA Closure Managing anticoagulation and antiplatelet therapy in patients undergoing percutaneous left atrial appendage closure with the Watchman device. BY JESSICA
More informationRole of cardiac imaging for catheterbased left atrial appendage closure
Role of cardiac imaging for catheterbased left atrial appendage closure Ana G. Almeida, MD, PhD Cardiology University Hospital Santa Maria, Lisbon Ana G. Almeida, MD, PhD, FESC University Hospital Santa
More informationTHINK OUTSIDE THE PILLBOX
WATCHMAN : A CLINICALLY PROVEN AND SAFE THERAPY FOR YOUR NVAF PATIENTS WATCHMAN reduces the risk of stroke in NVAF patients as effectively as warfarin WATCHMAN also reduces the long-term risk of bleeding
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationDevices to Protect Against Stroke in Atrial Fibrillation
Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria
More informationLAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC
LAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC INTERVENTIONAL CARDIOLOGIST DIRECTOR, ADULT CARDIOLOGY FELLOWSHIP TRAINING
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationWatchman. Left Atrial Appendage Closure Device. Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8
TM Watchman Left Atrial Appendage Closure Device PROOF OFLEADERSHIP Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8 Patients with AF have a 5x increased risk of stroke.
More informationTHINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
More informationTHINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationLAmbre LAA Occluder Updates
LAmbre LAA Occluder Updates 4 th Asia Pacific Congenital & Structural Interventional Symposium 6 th June, 2013 Hong Kong Yat-yin LAM MBBS MRCP FHKCP FHKAM FESC FRCP FACC MD Associate Professor, Prince
More informationAppendage Closure. Jason Rogers, MD. Director, Interventional Cardiology UC Davis Medical Center Sacramento, California
Appendage Closure Jason Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Sacramento, California Left Atrium: Atrial Fibrillation Left Atrial Appendage Left Atrium Incidence of Atrial
More informationAtrial fibrillation (AF), one of the
Hellenic J Cardiol 2013; 54: 408-412 Case Report Left Atrial Appendage Occlusion with the Amplatzer Amulet for Stroke Prevention in Atrial Fibrillation: The First Case in Greece Apostolos Tzikas, Lambros
More informationModern aspects in multidisciplinary thromboembolic prophylaxis. AMPLATZER Left Atrial Appendage data update
Modern aspects in multidisciplinary thromboembolic prophylaxis AMPLATZER Left Atrial Appendage data update Igal Moarof, MD Interventional Cardiology Kantonsspital Aarau Potential conflicts of interest
More informationFilling the gap: interventional occlusion of incompletely ligated left atrial appendages
Europace (2015) 17, 64 68 doi:10.1093/europace/euu164 CLINICAL RESEARCH Ablation for atrial fibrillation Filling the gap: interventional occlusion of incompletely ligated left atrial appendages Stefano
More informationWatchman a Stroke Prevention Technology for Patients with Atrial Fibrillation
Watchman a Stroke Prevention Technology for Patients with Atrial Fibrillation Scripps hospital,la Jolla, CA Atrial fibrillation is a major source of cardiogenic embolic related stroke 500,000 strokes per
More informationContinuing Cardiology Education
Continuing Cardiology Education REVIEW ARTICLE Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: indications diversity and future perspectives A. Tzikas 1 & T.
More informationLeft-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Medical Policy Manual Surgery, Policy No. 195 Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Next Review: November 2019 Last Review: January 2019 Effective: February
More informationLeft Atrial Appendage Closure Devices. Atrial Fibrillation 10/11/2017
Left Atrial Appendage Closure Devices Emile Daoud, MD Chief, Cardiac Electrophysiology Wexner Medical Center, The Ohio State University Atrial Fibrillation 1 Adjusted Annual Stroke Risk Using CHA 2 DS
More informationIntroduction EP WIRE. ... Keywords
Europace (217), 1 6 doi:1.3/europace/eux254 EP WIRE Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association
More informationLeft Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation Zoltan G. Turi, M.D. Rutgers Robert Wood Johnson Medical School New Brunswick, NJ Disclosure Information Zoltan G.
More informationLeft atrium appendage closure: A new technique for patients at high hemorrhagic risk
Left atrium appendage closure: A new technique for patients at high hemorrhagic risk Victoria Martin Yuste MD PhD ITC. Cardiology Department. Hospital Clinic. Barcelona SITE. Barcelona, Juin-9-2013 NON
More informationLeft Atrial Appendage Closure: Techniques and Guidelines. Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA
Left Atrial Appendage Closure: Techniques and Guidelines Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA May is Stroke Awareness Month 2 September is AF Awareness Month Lecture Highlights
More informationEndocardial LAA Occlusion: Which Device for Which Patient?
Endocardial LAA Occlusion: Which Device for Which Patient? Roy Beinart, MD Davidai Arrhythmia Center The Leviev Heart Center Sheba Medical Center Sheba Medical Center Tel Hashomer The Leviev Heart Center
More informationLeft atrial appendage closure with the Amplatzer Cardiac Plug: Rationale for a higher degree of device oversizing at implantation
ORIGINAL ARTICLE Cardiology Journal 2015, Vol. 22, No. 2, 201 205 DOI: 10.5603/CJ.a2014.0063 Copyright 2015 Via Medica ISSN 1897 5593 Left atrial appendage closure with the Amplatzer Cardiac Plug: Rationale
More informationLeft atrial appendage occlusion
Kardiologie Left atrial appendage occlusion Mischa Kühne Kardiolunch, 10.9.2015 Overall stroke rate 5% per year CHA 2 DS 2 VASC score Most AF patients need protection from stroke ESC guidelines AF, 2010/2012
More informationLeft Atrial Appendage Closure
Left Atrial Appendage Closure Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org Risk Factors for Stroke From The Perspective
More informationUpdate in Left Atrial Appendage Occlusion: More Options
Update in Left Atrial Appendage Occlusion: More Options Sajjad A Sabir, MD Director, Structural Heart Disease Program Director, Interventional Echocardiography Director, Heart Valve Clinic Non-Valvular
More informationLeft Atrial Appendage Occlusion in the Era of Novel Anticoagulants
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Heart Institute, Cedars-Sinai Medical Center,
More informationCase Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device
273 Case Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device Amena Hussain MD, Muhamed Saric MD, Scott Bernstein MD, Douglas Holmes MD, Larry Chinitz MD NYU Langone Medical Center, United
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE ECHOCARDIOGRAPHY IN INTERVENTIONAL CARDIOLOGY
ATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE Aristides G. Panlilio, MD, FPCP, FPCC,FPSE, FASE Philippine Heart Center Chinese General Hospital and Medical Center
More informationUpdate in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
More informationWatchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg
Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure
More informationMEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT POLICY GUIDELINES DESCRIPTION. Page: 1 of 9
Page: 1 of 9 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES Policy Number 7.01.92 Category Technology assessment Effective Date 08/20/15 Revised
More informationLeft Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE
Left Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE Adam Greenbaum, MD NCVH Detroit 2015-09-12 Disclosures Former proctor: SentreHEART Discussion may include the use of non-fda approved devices
More informationPercutaneous Epicardial LAA Closure: When Does it Make Sense?
Percutaneous Epicardial LAA Closure: When Does it Make Sense? Petr Neuzil, MD,PhD, FESC Professor of Medicine Cardiology department Na Homolce Hospital, Prague, Czechia petr.neuzil@gmail.com Disclosures
More informationCommercial Products Percutaneous left atrial appendage closure is considered medically necessary when the criteria above is met.
Medical Coverage Policy Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation EFFECTIVE DATE: 07 01 2016 POLICY LAST UPDATED: 09 04 2018 OVERVIEW Stroke prevention
More informationDevices for Stroke Prevention. Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP
Devices for Stroke Prevention Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP Overview Left Atrial Appendage Closure FDA Approved Watchman Investigational Amulet PFO Closure Atrial Fibrillation
More informationSHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY
SHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY SHARED DECISION MAKING: AN EVIDENCE BASED CORNERSTONE OF LAAC THERAPY Shared decision making is a collaborative process that allows
More informationPercutaneous Left Atrial appendage occlusion and anticoagulation therapy Nicolas Lellouche, MD, PhD
Percutaneous Left Atrial appendage occlusion and anticoagulation therapy Nicolas Lellouche, MD, PhD Fédération de Cardiologie Hôpital Henri Mondor Créteil Atrial Fibrillation is a major cause of Stroke
More informationChapter 76 Left Atrial Appendage Closure: Indication and Technique
Chapter 76 Left Atrial Appendage Closure: Indication and Technique RANJAN SHETTY INTRODUCTION Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, which affects around 3% 5% of the population
More informationLeft atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives
Review Article Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives Bin Kong 1,2, Yu Liu 1,2, He Huang 1,2, Hong Jiang 1,2, Congxin
More informationMEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES EFFECTIVE DATE: 08/20/15 REVISED DATE: 10/20/16, 11/16/17
MEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL CATEGORY: Technology assessment PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.
More informationLeft Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016
Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016 Jesse Jorgensen, MD, FACC Director, Cardiac Cath Lab, Greenville Health System Disclosures
More informationDad needed to get off his blood thinner. His doctor told us about an alternative. It s called
Dad needed to get off his blood thinner. His doctor told us about an alternative. It s called A one-time procedure that may reduce stroke risk for a lifetime in people with AFib not caused by a heart valve
More informationPrimary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC
Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion Greg Francisco, MD, FACC DISCLOSURES None to declare Estimated 33.5million have AF worldwide (6-7million in
More informationTechnique, Risk, and Benefit. T. Santoso University of Indonesia Medical School,
Left Atrial Appendage Closure Technique, Risk, and Benefit T. Santoso University of Indonesia Medical School, Medistra Hospital, Jakarta, Indonesia Percutaneous LAA Closure Devices PLAATO (no longerdeveloped)
More informationPREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation
PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation Dr. Saibal Kar, MD TCT 2017 Late Breaking Clinical
More informationMedical Policy Manual. Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation. Date of Origin: December 2011
Medical Policy Manual Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Date of Origin: December 2011 Section: Medicine Last Reviewed Date: October 2013 Policy No:
More informationDevice-associated thrombus after percutaneous left atrial appendage closure: a case report and literature review
CSE REPORT Iwona Świątkiewicz, Marek Woźnicki, dam Sukiennik, Jacek Kubica Department of Cardiology and Internal Medicine, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, ydgoszcz, Poland
More informationLEFT ATRIAL APPENDAGE CLOSURE INSTEAD OF ANTICOAGULATION; INDICATIONS AND OUTCOMES. Sheetal Chandhok, MD
LEFT ATRIAL APPENDAGE CLOSURE INSTEAD OF ANTICOAGULATION; INDICATIONS AND OUTCOMES Sheetal Chandhok, MD Disclosures Boston Scientific: Speaker (Watchman) Trainer (Watchman) SentreHeart Primary Investigator
More informationPercutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Policy Number: 2.02.26 Last Review: 6/2014 Origination: 1/2012 Next Review: 12/2014 Policy Blue Cross and
More informationIs there a role for transcatheter left atrial appendage occlusion?
REVIEW Review Is there a role for transcatheter left atrial appendage occlusion? For patients with atrial fibrillation, successful warfarin therapy is difficult in clinical practice. Thus, it seems logical
More informationLeft Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Percutaneous Left Atrial Appendage Closure Device Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Percutaneous Left Atrial Appendage Closure Devices
More informationLeft Atrial Appendage Closure 4 questions Who? When? How? Results?
Left Atrial Appendage Closure 4 questions Who? When? How? Results? David R. Holmes, Jr., M.D. Mayo Clinic, Rochester ACC New York CVS New York, NY December 2017 2012 MFMER slide-1 Presenter Disclosure
More informationAtrial fibrillation (AF) is a common arrhythmia worldwide
Left Atrial Appendage Closure Under Intracardiac Echocardiographic Guidance: Feasibility and Comparison With Transesophageal Echocardiography Yae Matsuo, MD;* Petr Neuzil, MD, PhD;* Jan Petru, MD; Milan
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Title: Reintroduction Overview: Watchman Speaker: Mario Goessl, MD, FACC, FAHA, FESC, FSCAI Minneapolis Heart Institute at Abbott Northwestern Hospital Date: Monday, October 24,
More informationJACC: CARDIOVASCULAR INTERVENTIONS VOL. 10, NO. 21, 2017 ª 2017 PUBLISHED BY ELSEVIER ON BEHALF OF THE
ª 2017 PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 http://dx.doi.org/10.1016/j.jcin.2017.06.072 STRUCTURAL: ATRIAL INTERVENTION FOCUS Percutaneous
More informationRate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
More informationEurope. Other LAA occlusion devices are in clinical development.
EXPERT REVIEW INTERVENTIONS FOR STRUCTURAL HEART DISEASE Left atrial appendage closure for stroke prevention in nonvalvular atrial fibrillation: rationale, devices in clinical development and insights
More informationCombined catheter ablation and left atrial appendage closure as a. treatment of atrial fibrillation
Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation Giulio Molon, MD FACC, FESC, Fellow ANMCO Card Dept, S.Cuore hospital Negrar
More informationLeft Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD
Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD Director of Interventional Cardiac Research Cedars Sinai Medical Center Disclosure Statement
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, Pennsylvania USA What does Guilty until Effective mean? A fact is a simple statement that everyone believes. It is innocent
More informationAtrial fibrillation (AF) remains the most common
The Spectrum of Devices for Percutaneous Left Atrial Appendage Occlusion A look at current and emerging nonpharmacologic stroke prevention therapies. BY LLUIS ASMARATS, MD, AND JOSEP RODÉS-CABAU, MD Atrial
More informationRole of Imaging in Complex LAA Closure Anatomies
Role of Imaging in Complex LAA Closure Anatomies Sameer Gafoor 1,2 1 Swedish Heart and Vascular: Ming Zhang, Paul Huang, Darryl Wells, Adam Zivin, John Petersen II, Madalena Petrescu, Nimish Muni, Eric
More informationListen to Your Heart. What Everyone Needs To Know About Atrial Fibrillation & Stroke. The S-ICD System. The protection you need
Listen to Your Heart The S-ICD System What Everyone Needs To Know About Atrial Fibrillation & Stroke The protection you need without Stroke. touching Are you your at heart risk? Increase your knowledge.
More informationPercutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Section Medicine
2.02.26 Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Section Medicine Effective Date August 29, 2014 Subsection Cardiology Original Policy Date July 6,
More informationAtrial Fibrillation. Atrial Fibrillation
Atrial Fibrillation Stroke and Blood Thinning Medications What else is available? Srinivas Iyengar, MD, FACC, with Boulder Heart Structural Heart Director, Boulder Community Health 303-622-5849 Atrial
More informationLeft Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation
Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Medicine
More informationCryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
More informationFabien Praz, Andreas Wahl, Sophie Beney, Stephan Windecker, Heinrich P. Mattle*, Bernhard Meier
Procedural Outcome after Percutaneous Closure of Patent Foramen Ovale using the Amplatzer PFO Occluder Without Intra-Procedural Echocardiography in 1,000 Patients Fabien Praz, Andreas Wahl, Sophie Beney,
More informationNCVH Birmingham 2013 August 24, Michael S. Bailey, MD Birmingham Heart Clinic
NCVH Birmingham 2013 August 24, 2013 Michael S. Bailey, MD Birmingham Heart Clinic NCVH Birmingham 2015 August 29, 2015 Michael S. Bailey, MD Birmingham Heart Clinic Left Atrial Anatomy Part of a larger
More informationRelevant Advances in Atrial Fibrillation
Gregory M Marcus, MD, MAS Assistant Professor of Medicine Division of Cardiology University of California, San Francisco Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Antiarrhythmic Drug
More informationAtrial fibrillation (AF) is the most common
Left Atrial Appendage Closure With the Watchman Device A review of trial results and clinical application. BY JAYANT KHITHA, MD, AND TANVIR K. BAJWA, MD Atrial fibrillation (AF) is the most common arrhythmia
More informationA PATIENT S GUIDE TO THE LEFT ATRIAL APPENDAGE CLOSURE. Reducing the risk of stroke in atrial fibrillation
A PATIENT S GUIDE TO THE LEFT ATRIAL APPENDAGE CLOSURE Reducing the risk of stroke in atrial fibrillation TABLE OF CONTENTS IMPORTANT Please Note: Information provided by Boston Scientific Corporation
More informationPercutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Last Review Status/Date: December 2015 Page: 1 of 17 Devices for Stroke Prevention in Atrial Description Stroke prevention in atrial fibrillation is an important consideration. Treatment with anticoagulant
More informationWatchman Implantation Case Presentation and Discussion
Watchman Implantation Case Presentation and Discussion Walid Saliba, MD, FHRS Director Atrial Fibrillation Center Co-Director AF Stroke Prevention Center Cleveland Clinic Indication FDA NonValvular AF
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationLeft Atrial Appendage Closure in SCRIPPS CLINIC
Left Atrial Appendage Closure in Atrial Fibrillation to Prevent Stroke Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org
More informationLeft Atrial Appendage Closure Techniques: 2015
Left Atrial Appendage Closure Techniques: 2015 Ramon Quesada, MD, FACP, FACC, FSCAI Medical Director, Interventional Cardiology & Cardiac Research Medical Director, Structural Heart and TAVR Program Baptist
More informationGauging stroke risk across the AF spectrum and selecting the appropriate patient for LAA closure. Miguel Valderrábano, MD
Gauging stroke risk across the AF spectrum and selecting the appropriate patient for LAA closure Miguel Valderrábano, MD Risk of Stroke in Atrial Fibrillation CHADS 2 -CHA 2 DS 2 -VASc Scores Adjusted
More informationPercutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Policy Number: 2.02.26 Last Review: 12/2018 Origination: 1/2012 Next Review: 12/2019 Policy Blue Cross and
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More information[N] = No product variation, policy applies as stated [Y] = Standard product coverage varies from application of this policy, see below
Original Issue Date (Created): July 26, 2011 Most Recent Review Date (Revised): November 26, 2013 Effective Date: February 1, 2014 I. POLICY The use of percutaneous left-atrial appendage closure devices
More informationTrick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT?
Trick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT? Disclosure SentreHeart, Inc Consultant Equity holder A cardiac disease that kills by producing emboli The most severe consequence
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationICE 2012 Ioannina,
ICE 2012 Ioannina, 15-12-2012 Case presentation Left Atrial Appendage Occlusion therapy for Stroke Prevention in Atrial Fibrillation Apostolos Tzikas MD, PhD, FESC Interventional Cardiology Congenital
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationTITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations
TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations DATE: 29 September 2010 CONTEXT AND POLICY ISSUES: Atrial fibrillation (AF) is the irregular, rapid beating of the
More informationLeft atrial appendage occlusion for stroke prevention in patients with atrial fibrillation
Received: 15 May 2017 Revised: 21 June 2017 Accepted: 26 June 2017 DOI: 10.1002/clc.22764 REVIEWS Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation Rizma Jalees
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationWhat the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More information